Adcendo
PrivateLast Round
Series C
Apr 14, 2026
Est. Valuation
$332,367
Total Funding Raised
$324.71M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Adcendo is a biotechnology company that develops antibody-drug conjugates aimed at creating innovative treatments for cancer patients facing significant unmet medical needs.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Adcendo Comps
Public and private peers based on sector, stage, and business model.
| Company | Status | Est. Valuation | Rev Multiple |
|---|---|---|---|
| OpenAI | Private | $86.0B | ~40x |
| Cohere | Private | $5.0B | -- |
| Competitor 1 | Public | $XX.XB | XXx |
| Competitor 2 | Public | $XX.XB | XXx |
Adcendo Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Apr 14, 2026 | ||||
| Series B | Nov 25, 2024 | ||||
| Series A Extension | May 29, 2024 | ||||
| Series A Extension | Apr 4, 2023 | ||||
| Series A | Apr 29, 2021 | ||||
Convertible Debt | Aug 29, 2019 |
Key People
Founding team and executive leadership
Adcendo Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Surveyor Capital | Series C, Series B |
| RA Capital Management | Series A, Series A Extension, Series C, Series B |
| TCG Crossover | Series C, Series B |
| Kohlberg Kravis Roberts | Series C |
| Novo Nordisk Foundation | Grant |
| Ysios Capital | Series A Extension, Series C, Series B, Series A |
| Pontifax Venture Capital | Series A Extension, Series C, Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 14, 2026
Rajul Jain from Vida Ventures joins the Board of Directors.
- Apr 14, 2026
Ksenija Pavletic joins the board, coming from Jeito Capital.
Adcendo Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Adcendo's valuation, stock price, and market status.